RxDoctor Payments Data

Eyvis Padin, NP

Family · Suffolk, VANPI 1790562932

Payments from drug & device makers

$2,768in general payments, 2019–2025

Across 115 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$404
  • AstraZeneca$293
  • Pfizer$230
  • Novartis$229
  • Sanofi$210
  • AbbVie$147
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,50190%
  • Education$26710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,768 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$9,673
Medicare patients
62
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide20$245,801
ImbruvicaIbrutinib14$216,764
EliquisApixaban19$12,703
Anastrozole78$1,242
Prochlorperazine Maleate32$944
Dexamethasone23$661
Ondansetron Hcl23$641
Doxycycline Hyclate12$571
Tamoxifen Citrate28$556
Lidocaine-PrilocaineLidocaine/Prilocaine26$339
Gabapentin30$319
Letrozole19$299
Oxybutynin Chloride13$206
LoperamideLoperamide Hcl11$128
Lorazepam14$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$64$245,80120 claims
PfizerEliquis$230$12,70319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →